Atherothrombosis
11
0
0
7
Key Insights
Highlights
Success Rate
78% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
18.2%
2 terminated out of 11 trials
77.8%
-8.7% vs benchmark
36%
4 trials in Phase 3/4
29%
2 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (11)
Optimal Antithrombotic Therapy in Ischemic Stroke Patients with Non-Valvular Atrial Fibrillation and Atherothrombosis
Comparison of Vascular Function in Emergency Service Professionals
Effect of Fire Suppression and Emergency Duties on Vascular Function
NEtwork to Control ATherothrombosis (NEAT Registry)
In-vivo Thrombus Imaging With 18F-GP1, a Novel Platelet PET Radiotracer
Effect of Real-fire Training on Vascular Function
Aspirin Resistance and Sleep Apnea in Type-2 Diabetic Patients
ASpirin vs Triflusal for Event Reduction In Atherothrombosis Secondary Prevention (ASTERIAS)
Pharmacogenomics of Antiplatelet Response - II (PARes-II)
Atherothrombosis Markers in Diabetics
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin